查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983691

基因檢測板市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Gene Panel Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因檢測市場價值將達到 37.7 億美元，到 2026 年將成長到 41.8 億美元，到 2032 年將達到 78.8 億美元，複合年成長率為 11.08%。

主要市場統計數據
基準年 2025 37.7億美元
預計年份：2026年 41.8億美元
預測年份 2032 78.8億美元
複合年成長率 (%) 11.08%

本報告清楚概述了基因檢測市場的現狀，重點關注技術融合、臨床應用以及檢測實驗室和公司領導者面臨的策略選擇。

基因組檢測生態系統正處於轉折點，其驅動力包括技術成熟、臨床應用以及不斷變化的監管預期。本執行摘要概述了當前形勢，並重點介紹了影響產品開發人員、檢查室管理人員和商業領導者策略規劃的關鍵主題。本報告的分析觀點著重於轉化價值、互通性以及將基因組學見解轉化為臨床和商業性成果的途徑。

平台成熟、自動化進步以及不斷變化的監管預期，是如何重塑整個基因檢測生態系統中價值創造和應用的路徑的？

近年來，隨著平台創新和新的臨床應用案例的逐步成熟，基因panel的格局發生了重塑。定序化學和樣品製備技術的進步降低了檢測的變異性，提高了對低表達靶點的靈敏度，推動了從單基因檢測到多重和多基因檢測的轉變。這種技術革新正在推動價值提案的更廣泛重構。如今，評估平台的標準不僅包括其處理能力，還包括其整合工作流程、與自動化系統的兼容性以及對下游資訊學和彙報的支援能力。

評估關稅如何改變基因面板相關人員的供應鏈重組和籌資策略，改變其採購動態和業務永續營運。

2025年美國關稅政策對依賴國際供應鏈採購試劑、定序設備及相關硬體的公司提出了結構性挑戰。關稅提高了進口零件的相對成本，促使買家重新評估其製造地，從而影響了籌資策略和供應商談判。為此，許多企業採取了雙重採購策略，並加強了與國內供應商的溝通，以維持利潤率和交貨時間。對於設備製造商而言，關稅促使他們重新評估零件標準化，以減少對受關稅影響零件的依賴。

全面的細分分析揭示了產品類型、技術、臨床應用和不同終端使用者群體的明確需求因素。

對市場區隔的詳細分析揭示了不同產品類型、技術、應用和最終用戶群體在採用模式和價值因素方面的差異。就產品類型而言，市場可細分為客製化檢測板、平台解決方案和現成產品線。客製化檢測板包括針對複雜診斷挑戰最佳化的多基因構建體，以及用於靶向、高靈敏度檢測的單基因檢測板。平台解決方案的特點是整合了可實現端到端自動化的系統和支援模組化工作流程的樣品製備盒。現成檢測板正變得越來越專業化，包括血液學檢測板、感染疾病板和固態腫瘤板，旨在簡化驗證和臨床報告流程。

美洲、歐洲、中東和非洲以及亞太地區的市場動態和法規環境會影響招募重點和策略市場進入決策。

區域趨勢帶來了獨特的營運環境、法律規範和臨床重點，這些都會影響產品開發和打入市場策略。在美洲，臨床效用與保險報銷的一致性至關重要，這促使轉化研究獲得大量投資，並在腫瘤臨床路徑中廣泛採用多基因檢測組合。北美檢查室通常優先考慮擴充性和監管認證，因此傾向於購買整合平台和經過檢驗的現成檢測組合，以加速臨床部署。這種環境也促進了診斷開發商與臨床網路之間的合作，以支持實證醫學的產生並與保險公司溝通。

企業級策略和競爭行為表明，平台整合夥伴關係和證據生成如何推動永續差異化。

關鍵的公司層面趨勢揭示了成熟企業和新興企業如何進行自我定位，以確保其長期競爭力。市場領導日益關注儀器、耗材和資訊學的整合平台生態系統，以減少檢驗和臨床部署過程中的阻力。策略性措施通常包括擴展服務和支援範圍、建立定期試劑供應計劃以及開發標準化的生物資訊流程，以提高可重複性和監管可追溯性。這些舉措降低了高通量檢查室採用端到端解決方案的門檻，同時也使供應商能夠透過耗材和軟體訂閱獲得持續收入。

為診斷開發人員和檢查室管理人員提供實用策略指南，以建立強大的價值鏈、加速臨床部署並最佳化平台價值提案。

為了將市場複雜性轉化為競爭優勢，產業領導者應採取組合策略，平衡平台投資與滿足臨床醫生和檢查室需求的特定應用產品和服務。優先開發整合工作流程，最大限度地減少人工操作時間並簡化檢驗，同時提供模組化選項，例如樣品製備盒，以滿足客戶對柔軟性的需求。投資於透明且檢驗的生物資訊流程和報告工具，以減少解讀差異並支持監管申報。

為了確保提供切實可行的見解，我們採用透明且可重複的調查方法，將與關鍵相關人員的訪談與嚴格的二次檢驗和迭代細分測試相結合。

本研究整合了定性訪談、文獻綜述和系統檢驗，旨在建構對基因檢測生態系統的全面理解。主要研究包括對檢查室管理人員、臨床醫生、平台供應商和供應鏈專家進行結構化訪談，以收集關於基因檢測應用障礙、營運需求和檢驗要求的第一手資料。二級資訊來源包括同行評審文獻、監管指導文件和企業資訊披露，以對技術能力和產品定位進行多角度檢驗。

透過整合強調技術證據和營運韌性應如何協調一致的結論，我們將基因面板創新轉化為永續的臨床和商業性影響。

總之，目前基因檢測技術的特點是平台功能、臨床需求和監管要求之間正迅速融合。定序和檢測化學技術的進步正在拓展其臨床應用範圍，同時也提高了證據生成、可重複性和對整合工作流程支援的要求。供應鏈趨勢和區域監管差異進一步增加了營運複雜性，任何商業策略都必須積極應對這些挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因檢測板市場：依產品類型分類

  • 自訂面板
    • 多基因檢測
    • 單基因檢測
  • 平台
    • 整合系統
    • 樣品製備工具包
  • 預製板
    • 血液疾病檢測
    • 感染疾病專家組
    • 固態腫瘤組

第9章 基因檢測市場：依技術分類

  • 微陣列
    • 比較基因組雜合反應陣列
    • SNP晶片
  • NGS
    • 擴增子序列
    • 混合捕獲序列
  • PCR
    • ddPCR
    • qPCR
  • 桑格定序

第10章 基因檢測板市場：依應用分類

  • 感染疾病
    • 細菌檢測板
    • 病毒面板
  • 腫瘤學
    • 液態生物檢體組合
    • 固態腫瘤組
  • 藥物基因體學
  • 罕見疾病
    • 遺傳疾病檢測
    • 神經系統疾病組

第11章 基因檢測市場：依最終用戶分類

  • 學術和研究機構
  • 診斷檢測實驗室
  • 醫院和診所
  • 製藥和生物技術公司

第12章 基因檢測板市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因檢測板市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因檢測板市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因檢測市場

第16章：中國基因檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • myGenomics
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • Novogene Co, Ltd.
  • PerkinElmer, Inc.
  • PrimBio Research Institute
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Product Code: MRR-FF012EDC38AC

The Gene Panel Market was valued at USD 3.77 billion in 2025 and is projected to grow to USD 4.18 billion in 2026, with a CAGR of 11.08%, reaching USD 7.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.77 billion
Estimated Year [2026] USD 4.18 billion
Forecast Year [2032] USD 7.88 billion
CAGR (%) 11.08%

A clear framing of the contemporary gene panel landscape highlighting technological convergence clinical adoption and the strategic choices facing laboratory and commercial leaders

The gene panel ecosystem is at an inflection point driven by technological maturation, clinical adoption, and shifting regulatory expectations. This executive summary introduces the landscape and frames the critical themes that shape strategic planning for product developers, laboratory directors, and commercial leaders. It establishes the analytical lens used throughout the report, emphasizing translational value, interoperability, and the pathways that convert genomic insights into clinical and commercial outcomes.

Early adopters and established players alike are navigating a mix of converging forces: innovation in sequencing and assay design, rising demand for precision diagnostics across oncology and infectious disease, and the need for robust laboratory workflows that support high-throughput, clinically accredited testing. As laboratories integrate multigene approaches alongside targeted single-gene assays, stakeholders must balance flexibility with reproducibility, and research-driven customization with regulatory-grade validation. The introduction sets expectations for the report's depth, highlights the importance of actionable segmentation, and outlines how subsequent sections will translate market dynamics into strategic choices for leaders and investors.

How platform maturation automation advances and evolving regulatory expectations are recalibrating value creation and adoption pathways across the gene panel ecosystem

Over the last several years the landscape for gene panels has reconfigured as platform innovation and new clinical use cases have matured in parallel. Advances in sequencing chemistry and library preparation have reduced assay variability and enhanced sensitivity for low-abundance targets, enabling a shift from single-gene tests toward multiplexed and multigene applications. This technological evolution has catalyzed a broader reorientation of value propositions: platforms are being evaluated not only for raw throughput but for integrated workflows, automation compatibility, and the ability to support downstream informatics and reporting.

Concurrently commercial dynamics have evolved. Diagnostic laboratories and hospital networks are increasingly prioritizing operational efficiency and interoperability, seeking platforms and consumables that facilitate rapid validation and scale. The emergence of hybrid capture and amplicon-based NGS approaches has expanded the range of applications, from solid tumor profiling to infectious disease surveillance and pharmacogenomics. Regulatory agencies are refining guidance around analytical and clinical validity, which shapes product development timelines and the evidentiary standards required for market adoption. As a result product developers are responding with predesigned panels optimized for specific indications while also offering customizable panels that allow clinicians and researchers to address unique diagnostic questions.

The interplay between platform providers and reagent kit manufacturers continues to reframe competitive dynamics. Integrated systems that deliver end-to-end solutions are capturing interest from high-throughput laboratories, whereas library prep kits and modular components retain appeal for centers seeking flexibility and cost control. Across applications a premium is being placed on reproducibility, speed to result, and the transparency of bioinformatic pipelines. Ultimately these transformative shifts are creating differentiated paths to adoption, where success depends on aligning technological capability with user workflows regulatory readiness and validated clinical utility.

Assessment of how tariff-driven supply chain realignments and sourcing strategies are reshaping procurement dynamics and operational resilience for gene panel stakeholders

United States tariff policy in 2025 introduced a structural consideration for firms that rely on international supply chains for reagents, sequencing instruments, and ancillary hardware. Tariffs influenced sourcing strategies and supplier negotiations by increasing the relative cost of imported components and prompting buyers to re-evaluate manufacturing footprints. In response many organizations initiated dual-sourcing strategies and intensified conversations with domestic suppliers to preserve margin and delivery timelines. For device manufacturers the tariffs incentivized a reevaluation of component standardization to reduce dependency on tariff-exposed parts.

Laboratories and service providers managing high-volume testing faced operational implications as procurement cycles lengthened and unit-level consumable planning became more complex. The need for inventory buffering increased lead times and required more sophisticated demand forecasting. These pressures accelerated interest in vendor-managed inventory models and long-term supply agreements that provide price predictability. Simultaneously, tariffs amplified the attractiveness of platform consolidation where fewer suppliers and integrated vendors could provide predictable, bundled pricing and support services that mitigate exposure to cross-border duty fluctuations.

From a strategic perspective organizations reassessed capital expenditure priorities and timeline sensitivities for instrument upgrades or validating new assays. The tariff environment also influenced partnership strategies: some companies sought regional manufacturing partnerships to localize production while others explored offshoring to jurisdictions with favorable trade agreements. Regulatory and reimbursement stakeholders observed these shifts as part of broader conversations about domestic manufacturing capacity and supply chain resilience, reinforcing the notion that supply chain strategy is now a core element of competitive positioning and risk mitigation for the gene panel sector.

Comprehensive segmentation analysis revealing distinct demand drivers across product typologies technologies clinical applications and the diverse spectrum of end users

A nuanced view of segmentation reveals differentiated adoption patterns and value drivers across product types, technologies, applications, and end users. When considering product type the market is organized across custom panels platform solutions and predesigned offerings. Custom panels span multigene constructs optimized for nuanced diagnostic questions as well as single gene panels that remain essential for targeted, high-sensitivity assays. Platforms are distinguished by integrated systems that provide end-to-end automation and library preparation kits that serve modular workflows. Predesigned panels are increasingly specialized with hematological panels infectious disease panels and solid tumor panels designed to streamline validation and clinical reporting.

Technology segmentation underscores distinct performance trade-offs and user preferences that inform procurement decisions. Microarray approaches continue to be relevant where comparative genomic hybridization arrays and SNP arrays offer cost-effective cytogenetic profiling. NGS technologies present a broad spectrum from amplicon sequencing suited for focused high-sensitivity targets to hybrid capture sequencing that supports comprehensive genomic coverage. PCR-based methods retain an essential role for rapid high-throughput screening with ddPCR and qPCR providing quantitative precision for low-input targets. Sanger sequencing remains a complementary orthogonal method for confirmatory testing where single-base resolution and established regulatory acceptance are critical.

Application-driven segmentation emphasizes clinical utility and laboratory workflow alignment. Infectious disease testing differentiates between bacterial panels and viral panels tailored for pathogen identification and resistance profiling. Oncology applications split into liquid biopsy panels enabling minimally invasive monitoring and solid tumor panels that support tissue-based molecular diagnostics. Pharmacogenomics centers on drug response panels that inform therapeutic selection while rare disease testing includes inherited disease panels and neurological disorder panels that require rigorous analytical validation and often necessitate bespoke interpretation pipelines. Across these applications, evidence generation and clinician engagement drive adoption curves.

End-user segmentation identifies distinct purchasing behaviors and evaluation criteria among academic and research institutes diagnostic laboratories hospitals and clinics and pharmaceutical and biotechnology companies. Academic and research institutes prioritize flexibility and exploratory capability with an emphasis on novel assay development and discovery. Diagnostic laboratories and clinical networks emphasize reproducibility accreditation and cost-per-test economics. Hospitals and clinics focus on integrated clinical workflows and rapid return of actionable results. Pharmaceutical and biotechnology companies seek panels that support companion diagnostic development translational studies and biomarker-enabled clinical trials. Understanding the interplay among these segmentation axes enables more precise product positioning and tailored commercial strategies.

Regional market dynamics and regulatory environments across the Americas Europe Middle East & Africa and Asia-Pacific that shape adoption priorities and strategic entry decisions

Regional dynamics introduce distinct operational environments regulatory frameworks and clinical priorities that influence product development and market entry strategies. In the Americas the emphasis is on clinical utility and reimbursement alignment, with significant investment in translational research and widespread integration of multigene panels in oncology pathways. North American laboratories often prioritize scalability and regulatory accreditation, shaping procurement decisions toward integrated platforms and validated predesigned panels that expedite clinical deployment. This environment also fosters collaborations between diagnostics developers and clinical networks to support evidence generation and payer engagement.

In Europe, Middle East & Africa regulatory heterogeneity and varied healthcare financing models drive region-specific adoption patterns. Several European markets place a premium on quality-assured workflows and harmonized testing standards, while emerging markets within the region balance cost containment with growing demand for infectious disease and rare disease diagnostics. The Middle East and Africa present both opportunities and challenges tied to infrastructure variability, prompting distributors and manufacturers to adapt service models and training programs to support local validation and implementation.

Asia-Pacific presents a diverse mosaic of advanced hubs and rapidly developing markets where capacity expansion and public health priorities shape demand. High-capacity centers in select markets pursue cutting-edge applications such as liquid biopsies and pharmacogenomics, whereas other markets prioritize infectious disease surveillance and cost-effective screening solutions. Regional supply chain considerations and local manufacturing initiatives influence procurement preferences, and collaborative public-private programs often catalyze broader access. Across all regions interoperability standards local regulatory expectations and reimbursement trajectories remain pivotal factors that influence strategic prioritization for manufacturers and service providers.

Company-level strategies and competitive behaviors showing how platform integration partnerships and evidence generation are driving sustainable differentiation

Key company-level trends reveal how incumbents and emerging entrants are positioning for long-term relevance. Market leaders increasingly emphasize platform ecosystems that integrate instruments consumables and informatics to reduce friction in validation and clinical implementation. Strategic initiatives commonly include expanding service and support offerings, establishing reagent continuity programs, and developing standardized bioinformatic pipelines to improve reproducibility and regulatory traceability. These moves lower barriers for high-throughput laboratories to adopt end-to-end solutions while enabling vendors to capture recurring revenue through consumables and software subscriptions.

Smaller and specialist companies are differentiating through focused verticalization and application-specific expertise. Firms that concentrate on hematological, infectious disease, or liquid biopsy panels invest in targeted clinical evidence and clinician education initiatives to accelerate acceptance. Collaboration remains a central motif as diagnostics firms partner with contract research organizations clinical laboratories and academic centers to co-develop panels, validate biomarkers, and support real-world evidence generation. Mergers and acquisitions continue to be a mechanism for consolidating complementary capabilities, acquiring specialized reagent technologies, or gaining regulatory footholds in new jurisdictions.

Across the competitive set there is sustained investment in quality management systems, regulatory affairs capacity, and post-market surveillance capabilities to meet evolving compliance expectations. Companies that succeed combine technical differentiation with robust commercialization frameworks that address validation pathways, payer engagement, and laboratory workflows. Intellectual property strategies focusing on assay chemistry, probe design, and bioinformatic algorithms provide defensive moats, while open collaboration on standards and interoperability can accelerate market expansion where adoption depends on cross-vendor compatibility.

Actionable strategic playbook for diagnostic developers and laboratory leaders to build resilient supply chains accelerate clinical adoption and optimize platform value propositions

To convert market complexity into competitive advantage, industry leaders should pursue a portfolio approach that balances platform investments with application-specific offerings that meet clinician and laboratory needs. Prioritize the development of integrated workflows that minimize hands-on time and simplify validation, while concurrently offering modular options such as library prep kits to serve customers who need flexibility. Invest in transparent and validated bioinformatic pipelines and reporting tools that reduce interpretation variability and support regulatory submissions.

Strengthen supply chain resilience by implementing diversified sourcing strategies, evaluating regional manufacturing partnerships, and exploring vendor-managed inventory models to stabilize availability and pricing. Align commercial strategies with clinical evidence generation by co-investing in targeted clinical studies and real-world data initiatives that demonstrate utility for oncology infectious disease and pharmacogenomics use cases. Engage payers and health systems early to understand reimbursement levers and to build health economic models that articulate value for result-driven care pathways.

Cultivate strategic partnerships across the ecosystem including laboratories, hospitals, and pharmaceutical companies to accelerate adoption and to integrate diagnostics into therapeutic decision-making. Maintain a rigorous regulatory and quality stance by expanding regulatory affairs expertise and establishing post-market surveillance to facilitate market entry and long-term compliance. Lastly focus on customer enablement through education programs technical support and implementation services that lower time-to-value and foster long-term customer loyalty.

Transparent and reproducible research methodology blending primary stakeholder interviews with rigorous secondary validation and iterative segmentation testing to ensure actionable insights

This research synthesizes primary qualitative interviews secondary literature mapping and methodical validation to construct a robust understanding of the gene panel ecosystem. Primary research involved structured interviews with laboratory directors clinicians platform vendors and supply chain specialists to capture first-hand insights on adoption barriers operational needs and validation requirements. Secondary sources included peer-reviewed literature regulatory guidance documents and company disclosures to triangulate technology capabilities and product positioning.

Data integrity was upheld through cross-validation across independent sources and by reconciling respondent perspectives with documented performance characteristics. Segmentation frameworks were iteratively tested with domain experts to ensure that product type, technology, application, and end-user categorizations reflect real-world procurement and clinical workflows. Limitations of the methodology include variations in publicly available evidence for newly launched products and the lag between clinical practice evolution and published validation studies. Where appropriate the analysis highlights areas requiring additional primary evidence to support definitive conclusions.

The research process emphasized transparency and reproducibility: methods, inclusion criteria, and interview guides are available to licensed purchasers seeking deeper methodological disclosure. Ethical practices and confidentiality protocols were followed throughout primary data collection to protect proprietary information while ensuring that synthesized insights remain actionable and generalizable for strategic decision-making.

Concluding synthesis that distills how technology evidence and operational resilience must align to convert gene panel innovation into sustained clinical and commercial impact

In conclusion the gene panel landscape is defined by accelerating convergence between platform capabilities clinical demand and regulatory expectations. Technological advancements in sequencing and assay chemistry have broadened clinical applicability while also raising the bar for evidence generation, reproducibility, and integrated workflow support. Supply chain dynamics and regional regulatory variability add layers of operational complexity that must be managed proactively as part of any commercial strategy.

Successful organizations will be those that align technical differentiation with validated clinical value, operational resilience, and tailored go-to-market approaches that reflect distinct end-user priorities and regional dynamics. Investment in robust bioinformatics, quality systems, and collaborative evidence-generation partnerships will be decisive factors in converting innovation into sustained adoption. The path forward requires disciplined execution across product development regulatory strategy and commercial engagement to realize the full potential of gene panels in advancing patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Panel Market, by Product Type

  • 8.1. Custom Panels
    • 8.1.1. Multigene Panels
    • 8.1.2. Single Gene Panels
  • 8.2. Platform
    • 8.2.1. Integrated Systems
    • 8.2.2. Library Prep Kits
  • 8.3. Predesigned Panels
    • 8.3.1. Hematological Panels
    • 8.3.2. Infectious Disease Panels
    • 8.3.3. Solid Tumor Panels

9. Gene Panel Market, by Technology

  • 9.1. Microarray
    • 9.1.1. Comparative Genomic Hybridization Arrays
    • 9.1.2. Snp Arrays
  • 9.2. Ngs
    • 9.2.1. Amplicon Sequencing
    • 9.2.2. Hybrid Capture Sequencing
  • 9.3. Pcr
    • 9.3.1. Ddpcr
    • 9.3.2. Qpcr
  • 9.4. Sanger Sequencing

10. Gene Panel Market, by Application

  • 10.1. Infectious Diseases
    • 10.1.1. Bacterial Panels
    • 10.1.2. Viral Panels
  • 10.2. Oncology
    • 10.2.1. Liquid Biopsy Panels
    • 10.2.2. Solid Tumor Panels
  • 10.3. Pharmacogenomics
  • 10.4. Rare Diseases
    • 10.4.1. Inherited Disease Panels
    • 10.4.2. Neurological Disorder Panels

11. Gene Panel Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Gene Panel Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Panel Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Panel Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Panel Market

16. China Gene Panel Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Genomics Co., Ltd.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. bioMerieux SA
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. Guardant Health, Inc.
  • 17.11. Illumina, Inc.
  • 17.12. myGenomics
  • 17.13. Myriad Genetics, Inc.
  • 17.14. NanoString Technologies, Inc.
  • 17.15. Natera, Inc.
  • 17.16. Novogene Co, Ltd.
  • 17.17. PerkinElmer, Inc.
  • 17.18. PrimBio Research Institute
  • 17.19. QIAGEN N.V.
  • 17.20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE PANEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE PANEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE PANEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE PANEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE PANEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE PANEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE PANEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE PANEL MARKET SIZE, BY MULTIGENE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE PANEL MARKET SIZE, BY MULTIGENE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE PANEL MARKET SIZE, BY MULTIGENE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE PANEL MARKET SIZE, BY SINGLE GENE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE PANEL MARKET SIZE, BY SINGLE GENE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE PANEL MARKET SIZE, BY SINGLE GENE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE PANEL MARKET SIZE, BY INTEGRATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE PANEL MARKET SIZE, BY INTEGRATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE PANEL MARKET SIZE, BY INTEGRATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE PANEL MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE PANEL MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE PANEL MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE PANEL MARKET SIZE, BY HEMATOLOGICAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE PANEL MARKET SIZE, BY HEMATOLOGICAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE PANEL MARKET SIZE, BY HEMATOLOGICAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE PANEL MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE PANEL MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE PANEL MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE PANEL MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE PANEL MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE PANEL MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE PANEL MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE PANEL MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE PANEL MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE PANEL MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE PANEL MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE PANEL MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE PANEL MARKET SIZE, BY HYBRID CAPTURE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE PANEL MARKET SIZE, BY HYBRID CAPTURE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE PANEL MARKET SIZE, BY HYBRID CAPTURE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE PANEL MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE PANEL MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE PANEL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE PANEL MARKET SIZE, BY DDPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE PANEL MARKET SIZE, BY DDPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE PANEL MARKET SIZE, BY DDPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE PANEL MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE PANEL MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE PANEL MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE PANEL MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE PANEL MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE PANEL MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE PANEL MARKET SIZE, BY BACTERIAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE PANEL MARKET SIZE, BY BACTERIAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE PANEL MARKET SIZE, BY BACTERIAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE PANEL MARKET SIZE, BY VIRAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE PANEL MARKET SIZE, BY VIRAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE PANEL MARKET SIZE, BY VIRAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE PANEL MARKET SIZE, BY LIQUID BIOPSY PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE PANEL MARKET SIZE, BY LIQUID BIOPSY PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE PANEL MARKET SIZE, BY LIQUID BIOPSY PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE PANEL MARKET SIZE, BY INHERITED DISEASE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE PANEL MARKET SIZE, BY INHERITED DISEASE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE PANEL MARKET SIZE, BY INHERITED DISEASE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE PANEL MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE PANEL MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE PANEL MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE PANEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE PANEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE PANEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE PANEL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE PANEL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE PANEL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE PANEL MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE PANEL MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE PANEL MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS GENE PANEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL GENE PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GCC GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 249. GCC GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 254. GCC GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. GCC GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. GCC GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. G7 GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 291. G7 GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. G7 GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 296. G7 GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. G7 GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 298. G7 GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. G7 GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 300. G7 GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 305. NATO GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. NATO GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 309. NATO GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 310. NATO GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. NATO GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 312. NATO GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. NATO GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 314. NATO GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)